Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients

Clinical Infectious Diseases

Volumn 26, Issue 3, 1998, Pages 576-583

  Winston, Drew J ^a   Bartoni, Kathy ^b   Bruckner, David A ^b   Schiller, Gary J ^b   Territo, Mary C ^b  

^a UCLA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; IMIPENEM; SULPERAZON;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RASH; SEIZURE; STAPHYLOCOCCUS AUREUS; SUPERINFECTION;

EID: 0031957062     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514578     Document Type: Article

References (22)

1. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986;315:552-8.
2. De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial. Ann Intern Med 1994;120:834-44.
3. Norrby SR, Vandercam B, Louie T, et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis Suppl 1987;52:65-78.
4. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991;115:849-59.
5. Rolston KVI, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
6. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-76.
7. Winston DJ, McGrattan MA, Busuttil RW. Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections. Antimicrob Agents Chemother 1984;26:673-7.
8. Liang R, Yung R, Chiu E, et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother 1990;34:1336-41.
9. Johnson MP, Ramphal R. Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990;162:981-3.
10. Williams JD. β-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. Clin Infect Dis 1997;24:494-7.
11. Bodey GP, Miller P, Ho DH. In vitro assessment of sulbactam plus cefoperazone in the treatment of bacteria isolated from cancer patients. Diagn Microbtol. Infect Dis 1989;12(suppl):209S-14S.
12. Chandrasekar PH, Sluchak JA, Kruse JA. Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistant Pseudomonas aeniginosa and Escherichia coli in granulocytopenic mice. Antimicrob Agents Chemother 1993;37:1927-30.
13. Horiuchi A, Hasegawa H, Kageyama T, et al. Efficacy of sulbactam/cefoperazone for the treatment of infections in patients with hematologic diseases. Diagn Microbiol Infect Dis 1989;12(suppl):S215-9.
14. Bodey GP, EIting LS, Narro J, et al. An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients. J Antimicrob Chemother 1993;32:141-52.
15. Rho JP, Castle S, Smith K, Bawdon RE, Norman DC. Effects of impaired renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam. J Antimicrob Chemother 1992;29:701-9.
16. Rogers JD, Meisinger MA, Ferber F, Calandra GB, Demetriades JL, Bland JA. Pharmacokinetics of imipenem and cilastatin in volunteers. Rev Infect Dis 1985;7(suppl 3):S435-46.
17. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. 6th ed. Washington, DC: American Society for Microbiology, 1995.
18. Dixon WJ, Massey SJ. Introduction to statistical analysis. 3rd ed. New York: McGraw-Hill, 1969.
19. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
20. Lau WK, Young LS, Black RE, et al. Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail. Am J Med 1977;62:959-66.
21. Hewitt WL, Berdischewsky M, Young LS, Conteas CJ, Winston DJ. A prospective controlled comparison of netilmicin and carbenicillin versus amikacin and carbenicillin in leukopenic patients. In: Gut JP, ed. Netilmicin symposium proceedings. Amsterdam: Excerpta Medica, 1979:97-102.
22. Winston DJ, Ho WG, Young LS, Hewitt WL, Gale RP. Piperacillin plus amikacin therapy vs carbenicillin plus amikacin therapy in febrile, granulocytopenic patients. Arch Intern Med 1982;142:1663-7.